Hopfner Robert Lorne

SEC source: 0001193125-26-421747 · ownership.xml · derivative · entry 6

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,062 shares

Expires 2034-05-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

SEC source: 0001193125-26-421747 · ownership.xml · derivative · entry 5

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,562 shares

Expires 2035-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001193125-26-421747 · ownership.xml · derivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,196 shares

Expires 2035-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.

F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.

SEC source: 0001193125-26-421747 · ownership.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,820

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-421747 · ownership.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-421747 · ownership.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001012975-25-000937 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 4,026

F1 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 14

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 294,502 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F8 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 13

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 36,812 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F7 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 12

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By NFLS Delta III Limited

Disclosed balance after: 0

Underlying: Common Stock · 36,812 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F5 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F6 · ownership.nature: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 11

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 267,367 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F7 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 10

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By NFLS Delta III Limited

Disclosed balance after: 0

Underlying: Common Stock · 240,756 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F6 · ownership.nature: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 9

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 908,821 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F3 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F7 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 8

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By NFLS Delta III Limited

Disclosed balance after: 0

Underlying: Common Stock · 324,578 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F3 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F6 · ownership.nature: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 7

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 419,441 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F7 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 6

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By NFLS Delta III Limited

Disclosed balance after: 0

Underlying: Common Stock · 838,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F6 · ownership.nature: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · derivative · entry 5

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 3,026 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F2 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · nonDerivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund II, L.P.

Disclosed balance after: 294,502

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F8 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · nonDerivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,632,441

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F3 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F4 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F5 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F7 · ownership.nature: Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By NFLS Delta III Limited

Disclosed balance after: 1,441,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F3 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F4 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F5 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F6 · ownership.nature: Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001551966-25-000007 · form4-11122025_091138.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 3,026

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F2 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-25-094089 · ownership.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F2 · shares: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.

F4 · ownership.nature: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F5 · ownership.nature: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

F6 · ownership.nature: Held directly by Pivotal bioVenture Partners Fund II, L.P.

SEC source: 0000950170-25-094089 · ownership.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F2 · shares: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.

F3 · ownership.nature: Held directly by Pivotal bioVenture Partners Fund I, L.P.

F4 · ownership.nature: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F5 · ownership.nature: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

SEC source: 0001739410-25-000083 · wk-form4_1747343196.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2035-05-13

F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001739410-25-000006 · wk-form4_1736201189.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,571

Underlying: Common Stock · 73,571 shares

Expires 2035-01-02

F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.

F2 · balance_after: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.

SEC source: 0000950170-24-075586 · ownership.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2034-06-17

F1 · derivative.exercise_date: The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

SEC source: 0001739410-24-000088 · wk-form4_1715979797.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2034-05-15

F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

SEC source: 0000950170-23-038268 · ownership.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal

Disclosed balance after: 1,571,741

F2 · ownership.nature: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F3 · ownership.nature: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

F4 · ownership.nature: Held directly by Pivotal bioVenture Partners Fund II, L.P.

SEC source: 0000950170-23-038268 · ownership.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal

Disclosed balance after: 2,923,110

F1 · ownership.nature: Held directly by Pivotal bioVenture Partners Fund I, L.P.

F2 · ownership.nature: The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F3 · ownership.nature: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-23-037295 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-12

F1 · derivative.exercise_date: The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

SEC source: 0000899243-23-013404 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,490

Underlying: Common Stock · 15,490 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 17, 2024 or the date of the Company's 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-029521 · doc4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal

Disclosed balance after: 3,661,518

F2 · ownership.nature: The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F3 · ownership.nature: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

F4 · ownership.nature: 2,804,062 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 857,456 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P.

SEC source: 0001209191-23-029521 · doc4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Pivotal

Disclosed balance after: 3,432,816

F1 · ownership.nature: 2,771,391 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 661,425 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal").

F2 · ownership.nature: The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F3 · ownership.nature: Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-23-021647 · doc4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,213,586

F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.14 to $4.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

F2 · ownership.nature: 2,740,072 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 473,514 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F3 · ownership.nature: Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-23-021559 · doc4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,868,994

F4 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.64 to $4.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (4).

F3 · ownership.nature: Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

F5 · ownership.nature: 2,690,845 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 178,149 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P.

SEC source: 0001209191-23-021559 · doc4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,712,228

F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.625 to $3.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

F2 · ownership.nature: 2,668,450 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 43,778 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

F3 · ownership.nature: Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-22-036568 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,367

Underlying: Common Stock · 9,367 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

SEC source: 0000899243-22-019829 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,440

Underlying: Common Stock · 13,440 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 24, 2023 or the date of the Company's 2023 Annual Meeting of Stockholders.

SEC source: 0001209191-22-024919 · doc4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 2,661,154

F1 · ownership.nature: The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL").

F2 · ownership.nature: The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Mr. Kin Ho Kwok, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

SEC source: 0000899243-22-001062 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,242

Underlying: Common Stock · 6,242 shares

Expires 2032-01-03

F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022.

SEC source: 0000899243-21-031635 · doc4.xml · nonDerivative · entry 2

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Pivotal bioVenture Partners Fund I L.P

Disclosed balance after: 2,267,411

F2 · ownership.nature: Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-031635 · doc4.xml · derivative · entry 4

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,440

Underlying: Common Stock · 13,440 shares

Expires not disclosed

F4 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031.

F4 · derivative.expiration_date: The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031.

SEC source: 0000899243-21-031635 · doc4.xml · derivative · entry 3

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Pivotal bioVenture Partners Fund I L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,693,488 shares

Expires not disclosed

F1 · derivative.exercise_price: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F1 · kind: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F1 · price: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F1 · derivative.exercise_date: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F1 · derivative.expiration_date: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F3 · derivative.underlying: Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into shares of common units of Rallybio Holdings, LLC.

F2 · ownership.nature: Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-031635 · doc4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Pivotal bioVenture Partners Fund I L.P

Disclosed balance after: 1,694,388

F1 · kind: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F1 · price: The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.

F2 · ownership.nature: Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-043005 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,367

Underlying: Common Stock · 9,367 shares

Expires 2031-06-22

F1 · derivative.exercise_date: The option was granted on June 23, 2021. The shares underlying the option are scheduled to vest as to 100% of the shares on June 23, 2022, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

SEC source: 0001209191-21-037905 · doc4.xml · derivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-01

F1 · derivative.exercise_date: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 9

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,405,418

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.11, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 8

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,412,050

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.27 to $28.26, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 7

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,419,617

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.27 to $27.26, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.

SEC source: 0001062993-21-001201 · form4.xml · nonDerivative · entry 6

Hopfner Robert Lorne · CIK 0001551966 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pivotal bioVenture Partners Fund I, L.P.

Disclosed balance after: 1,446,305

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.27 to $26.26, inclusive.

F3 · ownership.nature: The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.